As of 2025-07-01, the Relative Valuation of Denali Therapeutics Inc (DNLI) is (80.75) USD. This relative valuation is based on P/E multiples. With the latest stock price at 14.10 USD, the upside of Denali Therapeutics Inc based on Relative Valuation is -672.7%.
The range of the Relative Valuation is (68.21) - (112.85) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.1x - 38.8x | 25.1x |
| Forward P/E multiples | 23.4x - 46.4x | 30.4x |
| Fair Price | (68.21) - (112.85) | (80.75) |
| Upside | -583.8% - -900.4% | -672.7% |
| Date | P/E |
| 2025-06-27 | -4.85 |
| 2025-06-26 | -4.98 |
| 2025-06-25 | -4.97 |
| 2025-06-24 | -4.95 |
| 2025-06-23 | -4.68 |
| 2025-06-20 | -4.77 |
| 2025-06-18 | -4.84 |
| 2025-06-17 | -4.81 |
| 2025-06-16 | -5.02 |
| 2025-06-13 | -5.00 |
| 2025-06-12 | -5.13 |
| 2025-06-11 | -5.22 |
| 2025-06-10 | -5.24 |
| 2025-06-09 | -5.03 |
| 2025-06-06 | -5.05 |
| 2025-06-05 | -4.89 |
| 2025-06-04 | -4.96 |
| 2025-06-03 | -4.79 |
| 2025-06-02 | -4.80 |
| 2025-05-30 | -4.55 |
| 2025-05-29 | -4.65 |
| 2025-05-28 | -4.48 |
| 2025-05-27 | -4.54 |
| 2025-05-23 | -4.61 |
| 2025-05-22 | -4.69 |
| 2025-05-21 | -4.70 |
| 2025-05-20 | -4.91 |
| 2025-05-19 | -4.78 |
| 2025-05-16 | -4.74 |
| 2025-05-15 | -4.87 |
| 2025-05-14 | -4.80 |
| 2025-05-13 | -4.90 |
| 2025-05-12 | -5.09 |
| 2025-05-09 | -4.94 |
| 2025-05-08 | -4.96 |
| 2025-05-07 | -4.92 |
| 2025-05-06 | -4.80 |
| 2025-05-05 | -5.49 |
| 2025-05-02 | -5.65 |
| 2025-05-01 | -5.52 |
| 2025-04-30 | -5.72 |
| 2025-04-29 | -5.67 |
| 2025-04-28 | -5.58 |
| 2025-04-25 | -5.39 |
| 2025-04-24 | -5.32 |
| 2025-04-23 | -5.11 |
| 2025-04-22 | -5.02 |
| 2025-04-21 | -4.52 |
| 2025-04-17 | -4.38 |
| 2025-04-16 | -4.31 |